Baptist Health South Florida

Scholarly Commons @ Baptist Health South Florida
All Publications
12-2021

Independently validated sex-specific nomograms for predicting
survival in patients with newly diagnosed glioblastoma: NRG
Oncology RTOG 0525 and 0825
Minesh Mehta
Baptist Health Medical Group; Miami Cancer Institute, mineshm@baptisthealth.net

Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications

Citation
Journal of Neuro-Oncology (2021) 155(3):363-372.

This Article -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health
South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly
Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net.

Journal of Neuro-Oncology (2021) 155:363–372
https://doi.org/10.1007/s11060-021-03886-5

CLINICAL STUDY

Independently validated sex‑specific nomograms for predicting
survival in patients with newly diagnosed glioblastoma: NRG
Oncology RTOG 0525 and 0825
Nirav Patil1 · Eashwar Somasundaram2 · Kristin A. Waite3 · Justin D. Lathia4,5 · Mitchell Machtay6 · Mark R. Gilbert7 ·
James R. Connor6 · Joshua B. Rubin8 · Michael E. Berens9 · Robin A. Buerki1 · Serah Choi1 · Andrew E. Sloan1,2,5 ·
Marta Penas‑Prado10 · Lynn S. Ashby11 · Deborah T. Blumenthal12 · Maria Werner‑Wasik13 · Grant K. Hunter14 ·
John C. Flickinger15 · Merideth M. Wendland16 · Valerie Panet‑Raymond17 · H. Ian Robins18 · Stephanie L. Pugh19 ·
Minesh P. Mehta20 · Jill S. Barnholtz‑Sloan1,2,3,21
Received: 15 September 2021 / Accepted: 25 October 2021 / Published online: 10 November 2021
This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021

Abstract
Background/purpose Glioblastoma (GBM) is the most common primary malignant brain tumor. Sex has been shown to be
an important prognostic factor for GBM. The purpose of this study was to develop and independently validate sex-specific
nomograms for estimation of individualized GBM survival probabilities using data from 2 independent NRG Oncology
clinical trials.
Methods This analysis included information on 752 (NRG/RTOG 0525) and 599 (NRG/RTOG 0825) patients with newly
diagnosed GBM. The Cox proportional hazard models by sex were developed using NRG/RTOG 0525 and significant
variables were identified using a backward selection procedure. The final selected models by sex were then independently
validated using NRG/RTOG 0825.
Results Final nomograms were built by sex. Age at diagnosis, KPS, MGMT promoter methylation and location of tumor
were common significant predictors of survival for both sexes. For both sexes, tumors in the frontal lobes had significantly
better survival than tumors of multiple sites. Extent of resection, and use of corticosteroids were significant predictors of
survival for males.
Conclusions A sex specific nomogram that assesses individualized survival probabilities (6-, 12- and 24-months) for patients
with GBM could be more useful than estimation of overall survival as there are factors that differ between males and females.
A user friendly online application can be found here—https://npatilshinyappcalculator.shinyapps.io/SexDifferencesInGBM/.
Keywords Glioblastoma · Nomogram · Survival · Sex differences

Introduction
Glioblastoma (GBM) represents 48.3% of all malignant
primary brain tumors [1]. Despite advances in both treatment and biological understanding, prognosis remains poor.
Other than the modest benefit demonstrated by the addition of temozolomide to radiotherapy, and TTField therapy
to chemoradiotherapy, modern-day regimens have not
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significantly improved overall survival in the past 40 years
[2–5]. According to an National Cancer Database study,
long-term survivorship (over three years) in those with GBM
is only ~ 9% [6].
While extent of resection, age at diagnosis, Karnofsky
performance status (KPS), O-6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation status and
presence of an IDH1 or IDH2 mutation are well-validated
prognostic factors, [7–9] more recently sex has been shown
to be an important prognostic factor for GBM with better survival outcomes observed in females [6, 10]. Males
have a higher incidence of GBM compared to females [1].
Transcriptome analysis has suggested the existence of sexspecific molecular subtypes for GBM indicating that the
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biological differences in disease likely extend beyond basic
hormonal differences [11].
Currently, two nomograms have been developed for predicting 6-, 12-, and 24- month survival in GBM patients
generally and in isocitrate dehydrogenase (IDH) wildtype
GBM patients specifically [12, 13]. These nomograms use
various demographic and biological factors as survival predictor variables including patient sex. We hypothesize that
a sex-specific analysis may result in a more accurate survival prediction nomogram as sex was found be a significant
predictor of survival in that analysis. The purpose of this
study was to develop and independently validate sex-specific
nomograms for estimation of individualized survival probabilities for GBM patients. We utilized data from 2 independent, recent, and non-overlapping NRG Oncology (formerly
RTOG) clinical trials, NRG/RTOG 0525 and NRG/RTOG
0825 [14, 15].

Methods
Study population
Exempt approval was obtained from the University Hospitals Institutional Review Board (IRB) for all analyses presented. De-identified data were provided by NRG Oncology
for the clinical trials NRG/RTOG 0525 and NRG/RTOG
0825 for which a written informed consent was obtained for
each study subject under IRB approved protocols for each
participating NRG study site [14, 15]. NRG/RTOG 0525
enrolled patients from January 2006 through June 2008;
NRG/RTOG 0825 from April 2009 through May 2011. The
two trials included information on 831 and 620 randomized
patients with newly-diagnosed GBM, respectively. For each
patient, the following variables were obtained: survival/
follow-up time in months, survival status (dead or alive),
progression-free survival time in months, progression-free
survival status (no progression or progressed/dead), age at
diagnosis (continuous), race (white, black, or other), sex
(male or female), KPS (70, 80, 90, or 100), extent of resection (total/gross, subtotal, or other), MGMT promoter methylation status (promoter unmethylated or methylated), total
number (0, 1, or ≥ 2) of comorbidities (heart problems, lung
problems, high blood pressure, bleeding problems, circulation problems, diabetes, kidney/urine problems, stroke, thyroid problems, seizure, psychological problems), location
of tumor within brain (frontal, temporal, parietal, occipital
or multiple), laterality (right, left or bilateral) and use of
corticosteroids (had to have received a stable or decreasing dose for the 5 days before study registration (yes/no)).
Other category of extent of resection included unknown,
biopsy, debulking, craniotomy etc. Overall, 88 patients with
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unknown MGMT promoter methylation status and 6 with
unknown laterality were excluded from this analysis.

Statistical analysis
Descriptive statistics were used to assess any differences in
patient characteristics and prognostic factors by sex using
t-tests for continuous variables and chi-square tests for categorical variables. Non-parametric equivalents were used
as appropriate. The analyses were performed using NRG/
RTOG 0525 as the training dataset and NRG/RTOG 0825
as the validation dataset. Both overall survival (OS) and
progression-free survival (PFS) were examined for the trial
dataset using the Kaplan–Meier method and were compared by sex using the log-rank test. Upon examination of
the Shoenfeld residuals by sex, the proportional hazards
assumption for all analyses by sex was not violated.
In the initial phase of nomogram development to select
prognostic factors, we fit a multivariable Cox proportional
hazards model by sex for both OS and PFS to the training set
(0525). Cox models were found to be superior for survival
prediction on these datasets in a previous publication [12],
and a multivariable Cox model with sex as a variable using
these datasets was reported in a previous publication [12].
In the first step, a model was fit by including every candidate survival predictor variable; in each subsequent step,
the model with the smallest Akaike information criterion
(AIC) score was chosen after removing one variable at a
time (backward selection). And the model was refit with the
remaining variables. This process was repeated until to the
point where removing any variable would increase the AIC
score. Criterion-based methods such as AIC are preferred
as they involve a wider search and compare models in a
preferable manner[16, 17]. The proportional hazards and
linearity assumptions were examined using Schoenfeld and
Martingale residuals. None of the variables included in the
final model appear to violate these assumptions. We used the
candidate variables retained by each sex specific Cox model
on the training set (NRG/RTOG 0525) as the predictors of
survival to independently validate (NRG/RTOG 0825) and
build nomograms for OS and PFS. The final selected models
were trained using the data from NRG/RTOG 0525 and were
independently validated using the data from NRG/RTOG
0825.
Calibration of the final models by sex for both OS and
PFS for both training and validation dataset was visually
evaluated by assigning all patients into quintiles of the
nomogram-predicted survival probabilities and plotting the
mean nomogram predicted survival probability against the
Kaplan–Meier estimated survival for each quintile. A userfriendly online application to obtain individualized predicted
survival probabilities by sex was developed and can be found
here—https://npatilshinyappcalculator.shinyapps.io/SexDi
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fferencesInGBM/. All analysis were performed using R
v3.6.0 (http://www.r-project.org/) and the online application was developed using R Shiny application.

Results
Patient characteristics
In both trials, treatment either did not affect primary outcomes (OS and PFS) or the outcomes did not reach the prespecified improvement target; therefore, the data from both
of the studies were used in this analysis (1,359 patients in
total across both trials). The comparison of patient characteristics between the trials is shown in Supplemental Table 1.
Table 1 shows the patient characteristics by sex by trial.
The proportion of males and females was similar in both
trials (57.7% vs 60.3% males and 42.3% vs 39.7% females
for NRG/RTOG 0525 and NRG/RTOG 0825, respectively).
Males tended to have higher KPS scores, poorer OS, poorer
PFS, and more cardiac co-morbidities. Tumor location
and laterality did not significantly differ by sex. Extent of
resection (EOR) also did not differ significantly by sex. The
majority of patients included in this analysis had no comorbidities (45.9%) and there was no significant difference in
total number of comorbidities by sex (Table 1).

Survival by the Kaplan–Meier method
Kaplan–Meier curves were generated for OS and PFS for
both NRG/RTOG 0525, the training dataset (Fig. 1 Panels
A and B) and NRG/RTOG 0825 (Fig. 1 Panels C and D),
the validation dataset. In the training dataset, females had a
median survival of 17.9 months (16.4–20.1), which differed
significantly from male OS of 13.8 months (12.4–14.9) (log
rank p = 0.003). Males also had poorer PFS of 5.8 months
(5.4–6.4) compared to female PFS of 6.4 months (5.8–8.3)
but this was not significant (log rank p = 0.06). In the validation dataset, females had a significantly greater median survival of 16.9 months (15.2–19.8) compared to male median
survival of 15.7 months (14.5–16.6, log rank p = 0.03).
The PFS was significantly different between females
(10.3 months, 8.7–12.3) and males (8.9 months, 7.8–9.9,
log rank p = 0.03). These differences in the median survival
were unadjusted estimates.

Sex differences in survival
The overall Cox model by sex with the variables selected
in the final model is shown in Table 2 for OS and Supplemental Table 4 for PFS. Based on the AIC criteria, age at
diagnosis, KPS, MGMT status and location of tumor were
common significant predictors of survival for both sexes.
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Extent of resection and use of corticosteroids were significant predictors of OS for males. However, for both sexes,
tumors in frontal lobe had significantly better survival than
tumors involving multiple sites. There was no difference in
survival between other sites and tumors of multiple sites.
Age, and MGMT status were also significant predictors for
PFS for both sexes.

Nomograms
Calibration curves were drawn for both training (NRG/
RTOG 0525) and validation (NRG/RTOG 0825) datasets
for predicted 6-, 12-, and 24-month overall survival by sex
(Supplemental Figs. 1 and 2). The curves show three lines,
blue (observed survival rates), gray (ideal survival rates),
and black (optimism/bias/ overfitting corrected survival
rates). The 12-month and 24-month survival, observed and
optimism corrected lines, are nearly identical showing near
perfect calibration for OS. A sex-specific nomogram was
developed for OS (Figs. 2 and 3). All nomograms were
developed using NRG/RTOG 0525 as the training data and
validated with NRG/RTOG 0825. The calibration curves
for validation datasets were plotted using parameters from
model using training dataset. The final multivariable model
for validation dataset is shown in Supplemental Table 3. The
calibration curves for PFS were not as accurate as those for
OS (Supplemental Figs. 3 and 4). In addition, progression
was determined by site investigator’s determination rather
than centrally reviewed PFS standards, hence reducing the
validity of this measure. For these reasons, we did not validate or construct nomograms for PFS.

Discussion
In this study, we sought to develop and independently validate, sex-specific individual prognostic nomograms for
patients with newly-diagnosed GBM. Our analysis includes
a large group of GBM patients from 2 modern clinical trials.
In the original NRG/RTOG 0525 and 0825 clinical trials,
OS and PFS were not significantly different in treatment or
control arms [14, 15]. This allowed us to train models on
0525 and externally validate using data from 0825 with no
further adjustment for treatment arms. For OS in the male
and female calibration curves, the ideal, bias-corrected, and
observed curves tracked closely to each other for training
and validation data. This suggests that the nomogram is
resistant to possible batch effect and overfitting. In addition,
the use of backward selection based on AIC to select only
the most important variables prevents overfitting from using
excess variables. In contrast, the calibration curves for PFS
were not as strong, therefore we did not develop nomograms.
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Table 1  Patient characteristics by NRG Oncology Trial and sex
NRG/RTOG 0525
(Training dataset)
Level
Age at diagnosis

Mean (SD)
Median (interquartile range)
Race, n (%)
Black
Other/Unknown
White
≤ 70
Karnofsky Performance Status 80
at registration,
90
n (%)
100
Extent of ResecTotal or Gross
tion, n (%)
total Resection
Partial or Subtotal
Other
Neurologic funcNo symptoms
tion, n (%)
Minor symptoms
Moderate symptoms
Severe
MGMT methylaMethylated
tion status, n (%) Unmethylated
Overall survival
Alive
status, n (%)
Dead
Overall Survival
Median (95% CI)
Time (months)*
Alive without
Progression-free
Pregression
survival status,
n (%)
Progressed or
death due to any
cause
Median (95% CI)
Progression-free
survival time
(months)*
Use of Steroids
Yes
Comorbidities
Heart problems
Yes
Lung problems
Yes
High blood presYes
sure
Bleeding problems Yes
Circulation probYes
lems
Diabetes
Yes
Kidney/urine
Yes
problems
Stroke
Yes
Thyroid problems Yes
Seizure
Yes
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NRG/RTOG 0825
(Validation dataset)

Male
(n = 434)

Female
(n = 318)

P-value

Male
(n = 361)

Female
(n = 238)

P-value

55.40 (12.13)
57.00 [48.00,
64.00]
7 (1.6)
98 (22.6)
329 (75.8)
44 (10.1)
98 (22.6)
176 (40.6)
116 (26.7)
243 (56.0)

56.29 (11.60)
58.00 [50.00,
64.00]
6 (1.9)
57 (17.9)
255 (80.2)
66 (20.8)
48 (15.1)
141 (44.3)
63 (19.8)
167 (52.5)

0.313a
0.242b

57.89 (11.01)
58.00 [52.00,
66.00]
3 (0.8)
9 (2.5)
349 (96.7)
38 (10.5)
96 (26.6)
161 (44.6)
66 (18.3)
212 (58.7)

57.32 (10.98)
58.00 [51.00,
64.00]
7 (2.9)
9 (3.8)
222 (93.3)
38 (16.0)
63 (26.5)
94 (39.5)
43 (18.1)
153 (64.3)

0.532a
0.369b

176 (40.6)
15 (3.5)
168 (38.7)
190 (43.8)
33 (7.6)

143 (45.0)
8 (2.5)
94 (29.6)
152 (47.8)
29 (9.1)

137 (38.0)
12 (3.3)
136 (37.7)
168 (46.5)
20 (5.5)

81 (34.0)
4 (1.7)
73 (30.7)
104 (43.7)
16 (6.7)

43 (9.9)
120 (27.6)
314 (72.4)
86 (19.8)
348 (80.2)
13.8 [12.4, 14.9]

43 (13.5)
119 (37.4)
199 (62.6)
76 (23.9)
242 (76.1)
17.9 [16.4, 20.1]

0.003d

37 (10.2)
100 (27.7)
261 (72.3)
109 (30.2)
252 (69.8)
15.7 [14.5, 16.6]

45 (18.9)
73 (30.7)
165 (69.3)
95 (39.9)
143 (60.1)
16.9 [15.2, 19.8]

38 (8.8)

33 (10.4)

0.532c

55 (15.2)

52 (21.8)

396 (91.2)

285 (89.6)

306 (84.8)

186 (78.2)

5.8 [5.4, 6.4]

6.4 [5.8, 8.3]

0.06d

8.9 [7.8, 9.9]

10.3 [8.7, 12.3]

0.03d

359 (82.7)

253 (79.6)

0.315c

261 (72.3)

176 (73.9)

0.726c

44 (10.1)
12 (2.8)
104 (24.0)

14 (4.4)
16 (5.0)
75 (23.6)

0.006c
0.154c
0.973c

47 (13.0)
16 (4.4)
138 (38.2)

17 (7.1)
15 (6.3)
80 (33.6)

0.032c
0.411c
0.288c

2 (0.5)
8 (1.8)

6 (1.9)
5 (1.6)

0.128c
0.999c

6 (1.7)
8 (2.2)

2 (0.8)
4 (1.7)

0.622c
0.873c

35 (8.1)
12 (2.8)

22 (6.9)
4 (1.3)

0.655c
0.246c

46 (12.7)
23 (6.4)

15 (6.3)
14 (5.9)

0.016c
0.944c

4 (0.9)
8 (1.8)
59 (13.6)

5 (1.6)
45 (14.2)
52 (16.4)

0.637c
13 (3.6)
c
< 0.001 21 (5.8)
0.343c
52 (14.4)

3 (1.3)
46 (19.3)
32 (13.4)

0.139c
< 0.001c
0.833c

0.292c

< 0.001c

0.41c

0.053c

0.006c
0.209c

0.091c

0.238c

0.249c

0.015c

0.488c
0.018c
0.03d
0.05c
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Table 1  (continued)
NRG/RTOG 0525
(Training dataset)

Psychological
problems
Total number of
Comorbidities

NRG/RTOG 0825
(Validation dataset)

Level

Male
(n = 434)

Female
(n = 318)

P-value

Male
(n = 361)

Female
(n = 238)

P-value

Yes

16 (3.7)

7 (2.2)

0.340c

12 (3.3)

7 (2.9)

0.981c

239 (55.1)
112 (25.8)
83 (19.1)
115 (26.5)

159 (50.0)
91 (28.6)
68 (21.4)
102 (32.1)

0.388c

128 (35.5)
132 (36.6)
101 (28.0)
83 (23.0)

95 (39.9)
79 (33.2)
64 (26.9)
61 (25.6)

0.525c

17 (3.9)
62 (14.3)
148 (34.1)
92 (21.2)
237 (54.6)
190 (43.8)
7 (1.6)

16 (5.0)
58 (18.2)
72 (22.6)
70 (22.0)
181 (56.9)
133 (41.8)
4 (1.3)

7 (1.9)
49 (13.6)
93 (25.8)
129 (35.7)
198 (54.8)
158 (43.8)
5 (1.4)

6 (2.5)
25 (10.5)
58 (24.4)
88 (37.0)
128 (53.8)
106 (44.5)
4 (1.7)

None
1
≥2
Location of Tumor Frontal Lobe
In Brain
Occipital Lobe
Parietal Lobe
Temporal Lobe
Multiple
Right
Laterality
Left
Bilateral

0.013c

0.780c

0.753c

0.936c

Overall Survival Time—Time since randomization to death/last follow-up
Progression-free survival time—Time since randomization to progression or date of death, or date of last-follow-up if alive without progression
88 patients with unknown MGMT status, 6 with unknown laterality, 2 with missing survival months and 8 with unknown location of tumor were
excluded
Very small number of patients had Liver disease (n = 12), HIV (n = 2) and infections (n = 9)
CI Confidence Interval
*
a
b
c
d

Kaplan Meier survival times
Independent t test
Mann-Whitney test
Chi-square test
Log rank test

Interestingly, the factors that contribute to PFS and OS
differ between males and females. Based on the final selected
variables, age of diagnosis, KPS score, MGMT-promoter
methylation status, extent of resection, use of corticosteroids, and location of the tumor in the brain are the significant
predictors of OS for males. However, extent of resection
was not a significant predictor of OS for females likely due
to very low sample size for females with ‘Other’ resection
(Table 1). For PFS, age at diagnosis, MGMT-promoter methylation status and extent of resection were significant survival predictors for males. In females, however, KPS score
was significant and extent of resection was not a significant
predictor of PFS. Similar to OS, the inconclusive p-values
for some variables were likely due to very low sample size
for both sexes.
While some of the variables for OS are the same for both
males and females, the relative importance of these factors
in terms of total points on the nomogram is different. The
total point distribution for age of diagnosis, MGMT promoter methylation status and KPS are significantly higher
for males compared to females indicating worse survival for

males compared to females. This finding is similar to what
has been reported earlier with these datasets, although these
results were not stratified by sex [12]. However, there are
some differences with respect to factors affecting survival
by sex. Interestingly, the impact of extent of resection is different between males and females, albeit this could be due
to lower sample size in females. Maximal extent of resection
is currently equally indicated regardless of sex. It should be
noted that extent of resection is a complex and somewhat
subjective variable that incorporates abilities of the treating neurosurgeon, tumor size, tumor location as it related
to proximity to eloquent cerebral cortex and other intracranial structures, dominant vs non-dominant laterality and the
patient’s general medical risks. Moreover, extent of resection
generally does not consider resected or residual non-contrast
enhancing disease.
Location of the tumor in the brain also had different
impact on OS and PFS between males and females. While
tumors in the frontal lobe had significantly better survival
probability compared to tumor involving multiple sites for
both sexes, tumors at the other locations did not have any

13

368

Journal of Neuro-Oncology (2021) 155:363–372

Fig. 1  Kaplan–Meier Survival Results by Sex for Overall and Progression-Free Survival Using Training (NRG/RTOG 0525) (A and B) and Validation (NRG/RTOG 0825) (C and D) datasets

advantage over tumors in multiple sites. Further research is
needed to validate this finding and to translate it to clinical
relevance as we did not see similar association in the validation dataset. Additionally, the total number of comorbidities
was not found to be significant for either sex possibly due
to the fact that a large number of patients included in these
trials did not have any comorbidity or only a small number
of patients had each comorbidity (Table 1). We examined the
univariate association of each of the comorbidity with OS by
sex and found that none of the comorbidities were significant, except lung disease which was marginally significant
(Supplemental Table 2). The impact of these comorbidities
on the survival should be investigated in future trials with a
larger sample size.
The primary limitations in our work include demographic differences between the two NRG clinical trials;
and the population of GBM patients as a whole. While the
patient demographics across both NRG trials are similar,
race distribution, extent of resection patterns, and number
of comorbidities varied between the studies. NRG/RTOG
0825, the validation set, had more white patients, greater
gross total resection, and fewer patient comorbidities. All
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of these factors have been repeatedly shown to be prognostic for GBM survival [12, 6, 8]. However, in both the
training (NRG/RTOG 0525) and validation (NRG/RTOG
0825) datasets, white patients were disproportionally
more represented compared to distribution of GBM in the
larger US p opulation7. This may be the reason race was not
found to be a significant factor. The patients in both trials
may not be fully representative of the entire GBM population due to trial eligibility requirements. NRG/RTOG
0525 and 0825 had KPS cutoffs at 60 and 70 respectively
and required adequate hematological, renal, and hepatic
function [14, 15]. As such, the nomograms may not be
predictive of survival in patients who have clinical characteristics different from the inclusion criteria of these
clinical trials. The presence of an IDH mutation defines
a separate entity from IDH-wildtype glioblastoma and is
prognostic of survival outcomes. However, these studies
predated routine testing of this biomarker and hence IDH
mutation status was not available for the trials used in
this study[9, 18]. Besides, IDH mutation only occurs in a
small proportion of GBMs, hence these nomograms would
be applicable for the majority of patients [19]. Finally,

348

40 (90.9%)
86 (87.8%)
139 (79.0%)
83 (71.6%)

192 (79.0%)
141 (80.1%)
15 (100.0%)

267 (85.0%)
81 (67.5%)

55 (73.3%)
293 (81.6%)

80 (87.0%)
79 (68.7%)
12 (70.6%)

53 (85.5%)
124 (83.8%

434

44
98
176
116

243
176
15

314
120

75
359

92
115
17

62
148

1.05
1.02

—
0.66
0.73

—
1.35

—
0.54

—
1.23
2.01

—
0.88
0.61
0.50

1.02

0.73, 1.49
0.76, 1.36

—
0.48, 0.91
0.39, 1.34

—
1.01, 1.81

—
0.42, 0.70

—
0.98, 1.54
1.17, 3.46

—
0.59, 1.30
0.42, 0.88
0.34, 0.74

1.01, 1.03

0.805
0.912

0.010
0.306

0.046

< 0.001

0.070
0.012

0.505
0.008
< 0.001

< 0.001

p-value

58
72

70
102
16

65
235

199
119

167
143
8

66
48
141
63

318

48 (82.8%)
55 (76.4%)

58 (82.9%)
69 (67.6%)
12 (75.0%)

46 (70.8%)
196 (77.5%)

164 (82.4%)
78 (65.5%)

119 (71.3%)
117 (81.8%)
6 (75.0%)

55 (83.3%)
40 (83.3%)
106 (75.2%)
41 (65.1%)

242

Died

0.77
0.79

—
0.62
0.87

—
—

—
0.51

—
—
—

—
0.68
0.53
0.51

1.03

HR1

0.52, 1.14
0.54, 1.15

—
0.44, 0.89
0.46, 1.64

—
—

—
0.38, 0.67

—
—
—

—
0.45, 1.03
0.38, 0.75
0.34, 0.76

1.02, 1.05

95% CI1

HR Hazard Ratio, CI Confidence Interval

Variables not included in the table were not included in the final model. Extent of Resection and Use of Corticosteroids were not included in the final model for females

Age at Diagnosis
Karnofsky
Performance
Status at
registration
<  = 70
80
90
100
Extent of
Resection
GTR
STR
Other
MGMT
methylation
status
Unmethylated
Methylated
Use of Corticosteroids
No
Yes
Location of
Tumor In
Brain
Multiple Sites
Frontal Lobe
Occipital
Lobe
Parietal Lobe
Temporal
Lobe

95% CI

N

HR

N

Died

Female Overall Survival

Male Overall Survival

Table 2  Final Multivariable Cox Proportional Hazards Results for Overall Survival by Sex using the Training Dataset (NRG/RTOG 0525)

0.191
0.223

0.009
0.673

—
—

< 0.001

—
—

0.067
< 0.001
0.001

< 0.001

p-value
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Fig. 2  Final nomogram of Overall Survival for Males built on training data (NRG/RTOG 0525) and independently validated on NRG/RTOG
0825

Fig. 3  Final nomogram of Overall Survival for Females built on training data NRG/RTOG 0525 and independently validated on NRG/RTOG
0825
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PFS in these older NRG/RTOG trials is based upon site
investigator determination rather than central reviewers.
Caution should be used when applying these nomograms
to patients who are demographically or medically different
from the population included in this analysis. Lastly, PFS
should not be presumed to be a reliable endpoint, as the
determination of progression was not by central review,
and may have included instances of pseudoprogression.
The differences in the nomograms by sex shown here
indicates that the prognosis of females and males may be different and that these nomograms are useful tools for estimating patient-level survival probabilities. To facilitate clinical
use of this nomogram, free software for its implementation
is provided (https://npatilshinyappcalculator.shinyapps.io/
SexDifferencesInGBM/). This tool will be useful to health
care providers in determining individualized survival probabilities by sex. Further research should be done to better
characterize the exact biological mechanisms underlying sex
differences in GBM.
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